Evidence map›Paper›PMID 28231782›Full record

Trial reportBMC endocrine disorders2017

Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial.

Muhammad M Hammami, Ahmed Yusuf

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC endocrine disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01170494 (Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01170494 nacompletednot on this map

Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels: A Randomized Controlled Trial

TypeinterventionalSponsorKing Faisal Specialist Hospital & Research CenterRan2013 to 2016Enrolled279ConditionsVitamin D DeficiencyArmsergocalciferol 2000 IU orally, daily, ergocalciferol 25000 IU oraly every 2 weeks, ergocalciferol 50000 IU orally every 4 weeks, ergocal1000 IU & cholecal 1000 IU orally daily, cholecalciferol 2000 IU orally daily
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Misleading localization byBMC endocrine disorders · 2021
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muhammad M HammamiClinical Studies and Empirical Ethics Department, King Faisal Specialist Hospital and Research Center, P O Box # 3354 (MBC 03), Riyadh, 11211, Saudi Arabia. Muhammad@kfshrc.edu.sa.
Ahmed YusufClinical Studies and Empirical Ethics Department, King Faisal Specialist Hospital and Research Center, P O Box # 3354 (MBC 03), Riyadh, 11211, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D (D) supplements are indispensable for its world-wide deficiency. Controversy continues on ergocalciferol (D2) and cholecalciferol (D3) relative potency as well as on dosing-schedule and sex role in raising 25-hydroxy D (25(OH)D) level, the best indicator of D status.

methodsWe randomized 279 adults to daily D2, D3, D2/D3, or placebo; 2-weekly D2 or D3; or 4-weekly D2 or D3 (250,000 IU over/140 days). Randomization sequence, stratified by body-mass-index (BMI) and sex, was concealed from study coordinators and participants who were then blinded to capsules' content. D2, D3, 25(OH)D2, and 25(OH)D3 Serum levels were determined blindly on days 0,1,2,3,4,7,14, and 2-weekly thereafter by high performance liquid chromatography assay. The results of 269 participants were available for analysis. Primary endpoint was area-under-the-curve (AUC) of 25(OH)D (25(OH)D2 + 25(OH)D3) adjusted for sex, BMI, and baseline 25(OH)D level.

resultsMean(SD) age was 33.0(8.5) year, 41% were males, and 85% completed follow-up. Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively. AUC from day 0 to 140 (AUC

conclusionsEffects of D2 and D3 supplements on 25 (OH)D level may be dosing-schedule and sex-dependent. D2-associated reduction in 25(OH)D3 level may be related to total 25(OH)D level rather than being D2-specific. D2 may be 25-hydroxylated faster than D3.

trial registrationClinicalTrial.gov identifier: NCT01170494 (registered July 25, 2010).

Indexed as

AdultCholecalciferolDietary SupplementsDose-Response Relationship, DrugErgocalciferolsFemaleHumansMalePlacebosSex FactorsTime FactorsVitamin DYoung Adult25-hydroxyvitamin DCholecalciferolErgocalciferolsPlacebosVitamin D25-hydroxyvitamin D2 level25-hydroxyvitamin D3 levelBMICholecalciferol supplementCreatinine productionD2 levelD3 levelDose effectErgocalciferol supplementSex effect

Identifiers

PMID28231782
PMCPMC5324269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.